Key Points
- CEO August Troendle sold 21,858 shares on Nov. 21 at an average price of $592.18 for about $12.94 million, trimming his stake by 2.56% to 833,627 shares (SEC filing).
- Medpace beat Q3 expectations, reporting $3.86 EPS and $659.9M revenue (revenue +23.7% YoY) and issuing FY2025 guidance of $14.600–14.860 EPS; the stock is trading near its 12‑month high while analysts hold a consensus "Hold" with a $487.18 target.
Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) CEO August Troendle sold 21,858 shares of the stock in a transaction on Friday, November 21st. The stock was sold at an average price of $592.18, for a total transaction of $12,943,870.44. Following the sale, the chief executive officer directly owned 833,627 shares in the company, valued at $493,657,236.86. This trade represents a 2.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Medpace Trading Up 4.5%
NASDAQ MEDP opened at $618.49 on Tuesday. The stock has a market capitalization of $17.42 billion, a price-to-earnings ratio of 43.25, a PEG ratio of 2.67 and a beta of 1.42. The stock has a 50-day moving average of $551.90 and a 200 day moving average of $436.91. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $625.00.
Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.50 by $0.36. The firm had revenue of $659.90 million for the quarter, compared to analysts' expectations of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The firm's revenue for the quarter was up 23.7% compared to the same quarter last year. During the same quarter last year, the company earned $3.01 EPS. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. Equities analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.
Hedge Funds Weigh In On Medpace
Large investors have recently bought and sold shares of the company. Invesco Ltd. boosted its position in shares of Medpace by 9.4% during the 1st quarter. Invesco Ltd. now owns 1,186,768 shares of the company's stock worth $361,596,000 after purchasing an additional 102,015 shares in the last quarter. AQR Capital Management LLC boosted its position in Medpace by 65.1% during the third quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company's stock worth $518,170,000 after acquiring an additional 404,226 shares during the last quarter. Wasatch Advisors LP grew its holdings in Medpace by 14.0% in the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company's stock valued at $296,853,000 after buying an additional 116,354 shares during the period. Mawer Investment Management Ltd. lifted its stake in shares of Medpace by 17.4% in the 2nd quarter. Mawer Investment Management Ltd. now owns 817,432 shares of the company's stock valued at $256,559,000 after purchasing an additional 121,213 shares in the last quarter. Finally, Baillie Gifford & Co. lifted its position in Medpace by 12.0% during the 3rd quarter. Baillie Gifford & Co. now owns 584,796 shares of the company's stock worth $300,679,000 after acquiring an additional 62,503 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company's stock.
Wall Street Analysts Forecast Growth
Several research analysts recently weighed in on the company. Zacks Research upgraded Medpace from a "hold" rating to a "strong-buy" rating in a research report on Monday, October 27th. UBS Group cut shares of Medpace from a "neutral" rating to a "sell" rating and increased their price objective for the stock from $300.00 to $305.00 in a research report on Tuesday, July 29th. Jefferies Financial Group raised their price target on Medpace from $400.00 to $450.00 and gave the stock a "hold" rating in a research report on Tuesday, September 9th. Rothschild & Co Redburn downgraded Medpace from a "buy" rating to a "neutral" rating and boosted their price objective for the company from $342.00 to $474.00 in a report on Wednesday, September 3rd. Finally, Robert W. Baird set a $613.00 target price on Medpace in a report on Friday, October 24th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, ten have given a Hold rating and four have issued a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $487.18.
Read Our Latest Report on Medpace
Medpace Company Profile
(
Get Free Report)
Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
